probucol has been researched along with Coronary Disease in 76 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Probucol with hydration decreases the CI-AKI incidence compared to hydration only in patients with coronary heart disease undergoing CAG or PCI." | 9.41 | Preventing contrast-induced acute kidney injury with probucol and hydration in patients with coronary heart disease: A systematic review and meta-analysis of randomized controlled trials. ( Cui, X; Liu, F; Mei, L; Qin, F; Wang, H; Xie, B; Yi, X; Zhang, J, 2023) |
| "This study was performed to explore the effects of probucol on contrast-induced acute kidney injury (CIAKI) in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI)." | 9.30 | Effects of probucol on contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. ( Ge, W; Lu, C; Shi, Y; Wang, Y; Xu, X; Yang, S, 2019) |
| "To investigate the preventive effect of probucol combined with hydration on contrast-induced nephropathy (CIN) in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI)." | 9.27 | The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study. ( Cong, H; Fu, N; Liang, M; Lin, W; Lu, C; Tian, F; Yang, S; Zhang, J; Zhang, P, 2018) |
| "Thirty-eight men with chronic coronary heart disease (CHD) aged 38 to 65 years (ten patients with attendant obliterating atherosclerosis of lower extremity vessels) were treated with the hypolipidemic drug probucol in a dose of 1000 mg/day for three months." | 7.67 | [Effect of probucol on lipid metabolism and the clinical course of ischemic heart disease and arteriosclerosis obliterans of the vessels of the lower extremities]. ( Diukov, IV; Dudaev, VA; Gorin, VV; Kliuchnikova, ZhI; Shingireĭ, MV, 1984) |
| "Long-term treatment with probucol induced marked regression of xanthoma in patients with both homozygous and heterozygous familial hypercholesterolemia despite a substantial accompanying decrease in high-density lipoprotein (HDL) cholesterol." | 7.67 | Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. ( Funahashi, T; Matsuzawa, Y; Tarui, S; Yamamoto, A; Yamashita, S, 1988) |
| "Probucol with hydration decreases the CI-AKI incidence compared to hydration only in patients with coronary heart disease undergoing CAG or PCI." | 5.41 | Preventing contrast-induced acute kidney injury with probucol and hydration in patients with coronary heart disease: A systematic review and meta-analysis of randomized controlled trials. ( Cui, X; Liu, F; Mei, L; Qin, F; Wang, H; Xie, B; Yi, X; Zhang, J, 2023) |
| "This study was performed to explore the effects of probucol on contrast-induced acute kidney injury (CIAKI) in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI)." | 5.30 | Effects of probucol on contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. ( Ge, W; Lu, C; Shi, Y; Wang, Y; Xu, X; Yang, S, 2019) |
| "To investigate the preventive effect of probucol combined with hydration on contrast-induced nephropathy (CIN) in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI)." | 5.27 | The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study. ( Cong, H; Fu, N; Liang, M; Lin, W; Lu, C; Tian, F; Yang, S; Zhang, J; Zhang, P, 2018) |
| "Thirty-eight men with chronic coronary heart disease (CHD) aged 38 to 65 years (ten patients with attendant obliterating atherosclerosis of lower extremity vessels) were treated with the hypolipidemic drug probucol in a dose of 1000 mg/day for three months." | 3.67 | [Effect of probucol on lipid metabolism and the clinical course of ischemic heart disease and arteriosclerosis obliterans of the vessels of the lower extremities]. ( Diukov, IV; Dudaev, VA; Gorin, VV; Kliuchnikova, ZhI; Shingireĭ, MV, 1984) |
| "Long-term treatment with probucol induced marked regression of xanthoma in patients with both homozygous and heterozygous familial hypercholesterolemia despite a substantial accompanying decrease in high-density lipoprotein (HDL) cholesterol." | 3.67 | Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. ( Funahashi, T; Matsuzawa, Y; Tarui, S; Yamamoto, A; Yamashita, S, 1988) |
| "The effect of discontinuation of long term (34-56 months) probucol treatment on serum lipids, lipoproteins and on the activity of postheparin plasma lipoprotein and hepatic lipase ahs been studied in 10 healthy males participating in a primary prevention programme of coronary heart disease." | 3.66 | Effect of probucol on the activity of postheparin plasma lipoprotein lipase and hepatic lipase. ( Huttunen, JK; Kumlin, T; Kuusi, T; Mattila, S; Miettinen, TA; Naukkarinen, V; Strandberg, T, 1981) |
| "02 for the dose-response relationship; P< or =0." | 2.71 | Effects of AGI-1067 and probucol after percutaneous coronary interventions. ( Bourassa, MG; Glass, M; Grégoire, J; Guertin, MC; L'Allier, PL; Lambert, J; Laramée, L; Lespérance, J; Reeves, F; Schwartz, L; Tardif, JC; Title, L, 2003) |
| "In probucol-treated patients, the cross-sectional area (CSA) narrowing of 67." | 2.70 | Impact of residual plaque burden after balloon angioplasty in the MultiVitamins and Probucol (MVP) trial. ( Bilodeau , L; Côté , G; Couturier , A; de Guise , P; Doucet , S; Gallo , R; Gosselin , G; Grégoire , J; Harel , F; Joyal , M; Lespérance , J; Tardif , JC, 2001) |
| "Probucol (0." | 2.68 | Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. ( Hashida, K; Ikeda, S; Miyagawa, M; Sekiya, M; Watanabe, K, 1996) |
| "Probucol was continued until follow-up angiography 24 weeks after PTCA." | 2.68 | Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. ( Daida, H; Kanoh, T; Kato, K; Kutsumi, Y; Kuwabara, Y; Nakata, Y; Nishikawa, H; Nishimura, S; Nishiyama, S; Ohshima, S; Seki, A; Takatsu, F; Tomihara, H; Yamaguchi, H; Yokoi, H, 1997) |
| " The daily dosage of probucol was 1 g divided into two 500 mg doses." | 2.65 | [A long-term (9 years) clinical study of the safety and efficacy of probucol, and an analysis of morbidity and mortality rates (author's transl)]. ( Cerimelle, BJ; Martz, BL; Taylor, HA; Tedeschi, RE, 1980) |
| "Several forms of dyslipidemia are associated with premature coronary artery disease (CAD) and other vascular disease." | 2.39 | Hyperlipidemia: perspectives in diagnosis and treatment. ( Gotto, AM; Yeshurun, D, 1995) |
| " Thus, long-term administration appears to suppress the progression of atherosclerotic vascular disease in this animal model." | 1.30 | Long-term probucol treatment reverses the severity of myocardial injury in watanabe heritable hyperlipidemic rabbits. ( Aoki, K; Hori, M; Hoshida, S; Igarashi, J; Kuzuya, T; Yamashita, N, 1997) |
| "Achilles tendon xanthoma diminished significantly." | 1.27 | Nonprogression of coronary artery atherosclerosis in homozygous familial hypercholesterolemia after 31 months of repetitive plasma exchange. ( Adolph, R; Glueck, CJ; Rice, V; Spitz, HB; Stein, EA, 1986) |
| "Probucol was administered for 4 months in 20 adult males with Type IIb HLP in a total daily dose of 1." | 1.26 | Effect of probucol on plasma lipids and lipoproteins in type IIb hyperlipoproteinemia. ( Bell, C; Hunninghake, DB; Olson, L, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (34.21) | 18.7374 |
| 1990's | 28 (36.84) | 18.2507 |
| 2000's | 17 (22.37) | 29.6817 |
| 2010's | 4 (5.26) | 24.3611 |
| 2020's | 1 (1.32) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, X | 1 |
| Xie, B | 1 |
| Wang, H | 1 |
| Liu, F | 1 |
| Mei, L | 1 |
| Qin, F | 1 |
| Zhang, J | 2 |
| Yi, X | 1 |
| Fu, N | 1 |
| Yang, S | 2 |
| Zhang, P | 1 |
| Liang, M | 1 |
| Cong, H | 1 |
| Lin, W | 1 |
| Tian, F | 1 |
| Lu, C | 2 |
| Wang, Y | 1 |
| Shi, Y | 1 |
| Xu, X | 1 |
| Ge, W | 1 |
| Liu, J | 1 |
| Li, M | 1 |
| Lu, H | 1 |
| Qiao, W | 1 |
| Xi, D | 1 |
| Luo, T | 1 |
| Xiong, H | 1 |
| Guo, Z | 1 |
| Kaminnyi, AI | 1 |
| Lankin, VZ | 2 |
| Perepelitsa, EI | 1 |
| Konovalova, GG | 2 |
| Samko, AN | 1 |
| Tikhaze, AK | 1 |
| Kukharchuk, VV | 1 |
| Belenkov, YN | 1 |
| Ge, CJ | 1 |
| Lü, SZ | 1 |
| Feng, LX | 1 |
| Huo, Y | 1 |
| Song, XT | 1 |
| Chen, X | 1 |
| Meng, K | 1 |
| Yuan, F | 1 |
| Nagai, Y | 2 |
| Yanagi, K | 1 |
| Yamashita, S | 3 |
| Takemura, K | 1 |
| Matsuzawa, Y | 2 |
| Tardif, JC | 3 |
| Grégoire, J | 1 |
| Schwartz, L | 1 |
| Title, L | 1 |
| Laramée, L | 1 |
| Reeves, F | 1 |
| Lespérance, J | 3 |
| Bourassa, MG | 2 |
| L'Allier, PL | 1 |
| Glass, M | 1 |
| Lambert, J | 2 |
| Guertin, MC | 1 |
| Kitai, T | 1 |
| Ishiwata, S | 2 |
| Yamaguchi, T | 1 |
| Braun, A | 1 |
| Zhang, S | 1 |
| Miettinen, HE | 1 |
| Ebrahim, S | 1 |
| Holm, TM | 1 |
| Vasile, E | 1 |
| Post, MJ | 1 |
| Yoerger, DM | 1 |
| Picard, MH | 1 |
| Krieger, JL | 1 |
| Andrews, NC | 1 |
| Simons, M | 1 |
| Krieger, M | 1 |
| Bilenko, MV | 1 |
| Khil'chenko, AV | 1 |
| Sirtori, CR | 2 |
| Calabresi, L | 1 |
| Baldassarre, D | 1 |
| Franceschini, G | 2 |
| Cefalù, AB | 1 |
| Averna, M | 1 |
| Veryard, C | 1 |
| Tanimoto, T | 1 |
| Duffy, SJ | 1 |
| Dart, AM | 1 |
| Miettinen, TA | 4 |
| Huttunen, JK | 4 |
| Strandberg, T | 4 |
| Naukkarinen, V | 4 |
| Mattila, S | 3 |
| Kumlin, T | 3 |
| Oliver, MF | 1 |
| Bradlow, BA | 1 |
| Chetty, N | 1 |
| Birnbaum, M | 1 |
| Baker, SG | 1 |
| Seftel, HC | 1 |
| Bobkova, VI | 1 |
| Lokshina, LI | 2 |
| Sidakova, MM | 1 |
| Tananova, GV | 2 |
| Fomchenkov, SI | 1 |
| Nash, DT | 1 |
| Dudaev, VA | 1 |
| Gorin, VV | 1 |
| Shingireĭ, MV | 1 |
| Kliuchnikova, ZhI | 1 |
| Diukov, IV | 1 |
| Kuusi, T | 2 |
| Tedeschi, RE | 1 |
| Martz, BL | 1 |
| Taylor, HA | 1 |
| Cerimelle, BJ | 1 |
| Opplt, JJ | 2 |
| Chick, LL | 1 |
| Opplt, MA | 1 |
| Bahler, RC | 1 |
| Henahan, J | 1 |
| Mc Caughan, D | 1 |
| Hunninghake, DB | 3 |
| Bell, C | 1 |
| Olson, L | 1 |
| Yeshurun, D | 1 |
| Gotto, AM | 2 |
| Kuo, PT | 2 |
| Malloy, MJ | 1 |
| Kane, JP | 1 |
| Kitazume, H | 1 |
| Ageishi, Y | 1 |
| Iwama, T | 1 |
| Kubo, I | 1 |
| Suzuki, A | 1 |
| Schneider, JE | 1 |
| Berk, BC | 1 |
| Gravanis, MB | 1 |
| Santoian, EC | 1 |
| Cipolla, GD | 1 |
| Tarazona, N | 1 |
| Lassegue, B | 1 |
| King, SB | 1 |
| Betteridge, DJ | 1 |
| Dodson, PM | 1 |
| Durrington, PN | 1 |
| Hughes, EA | 1 |
| Laker, MF | 1 |
| Nicholls, DP | 1 |
| Rees, JA | 1 |
| Seymour, CA | 1 |
| Thompson, GR | 1 |
| Winder, AF | 1 |
| O'Keefe, JH | 1 |
| Stone, GW | 1 |
| McCallister, BD | 2 |
| Maddex, C | 1 |
| Ligon, R | 1 |
| Kacich, RL | 1 |
| Kahn, J | 1 |
| Cavero, PG | 1 |
| Hartzler, GO | 1 |
| Watanabe, K | 2 |
| Sekiya, M | 2 |
| Ikeda, S | 1 |
| Miyagawa, M | 2 |
| Hashida, K | 1 |
| Cöté, G | 2 |
| Bourassa, M | 1 |
| Doucet, S | 2 |
| Bilodeau, L | 2 |
| Nattel, S | 1 |
| de Guise, P | 1 |
| Libby, P | 1 |
| Ganz, P | 1 |
| Yokoi, H | 2 |
| Daida, H | 2 |
| Kuwabara, Y | 2 |
| Nishikawa, H | 2 |
| Takatsu, F | 2 |
| Tomihara, H | 1 |
| Nakata, Y | 2 |
| Kutsumi, Y | 2 |
| Ohshima, S | 1 |
| Nishiyama, S | 2 |
| Seki, A | 1 |
| Kato, K | 2 |
| Nishimura, S | 2 |
| Kanoh, T | 2 |
| Yamaguchi, H | 2 |
| Hoshida, S | 1 |
| Yamashita, N | 1 |
| Igarashi, J | 1 |
| Aoki, K | 1 |
| Kuzuya, T | 1 |
| Hori, M | 1 |
| Jay, SJ | 1 |
| Lisi, DM | 1 |
| Edelman, ER | 1 |
| Rodés, J | 1 |
| Bertrand, OF | 1 |
| Harel, F | 1 |
| Gallo, R | 1 |
| Rashdan, I | 1 |
| Funada, J | 1 |
| Akutsu, H | 1 |
| Kanaki, T | 1 |
| Saito, Y | 1 |
| Fukuzawa, S | 1 |
| Ozawa, S | 1 |
| Inagaki, M | 1 |
| Morooka, S | 1 |
| Inoue, T | 1 |
| Merchán Herrera, A | 1 |
| López Mínguez, JR | 1 |
| Alonso Ruiz, F | 1 |
| Escola, JM | 1 |
| Címbora Ortega, A | 1 |
| Poblador Curto, MA | 1 |
| Redondo Méndez, A | 1 |
| Romero Santisteban, R | 1 |
| Geniz Gallardo, I | 1 |
| González Fernández, R | 1 |
| Millán Núñez, V | 1 |
| Oshima, S | 1 |
| Miyauchi, K | 1 |
| Titov, VN | 1 |
| Zaĭtseva, TM | 1 |
| von Hodenberg, E | 1 |
| Tost, B | 1 |
| Scheffold, T | 1 |
| Pfuetze, KD | 1 |
| Dujovne, CA | 1 |
| Tardif , JC | 1 |
| Côté , G | 1 |
| Lespérance , J | 1 |
| Gosselin , G | 1 |
| Joyal , M | 1 |
| de Guise , P | 1 |
| Bilodeau , L | 1 |
| Doucet , S | 1 |
| Harel , F | 1 |
| Couturier , A | 1 |
| Gallo , R | 1 |
| Grégoire , J | 1 |
| Ogaki, S | 1 |
| Matsushima, T | 1 |
| Itakura, H | 2 |
| Grundy, SM | 2 |
| Vanhanen, H | 1 |
| Islami, Y | 1 |
| Ribeiro, LG | 1 |
| Naito, HK | 1 |
| Funahashi, T | 1 |
| Yamamoto, A | 1 |
| Tarui, S | 1 |
| Jones, PH | 1 |
| Scott, LW | 1 |
| Wilson, AC | 1 |
| Kostis, JB | 1 |
| Moreyra, AE | 1 |
| Maiorov, VN | 1 |
| Baranich, II | 1 |
| Silonova, VB | 1 |
| Eder, HA | 1 |
| Stein, EA | 1 |
| Adolph, R | 1 |
| Rice, V | 1 |
| Glueck, CJ | 1 |
| Spitz, HB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy: A Randomized, Multicenter, Multinational Study[NCT01291641] | Phase 4 | 342 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
21 reviews available for probucol and Coronary Disease
| Article | Year |
|---|---|
Preventing contrast-induced acute kidney injury with probucol and hydration in patients with coronary heart disease: A systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Kidney Injury; Contrast Media; Coronary Angiography; Coronary Disease; Drug-Related Side Effec | 2023 |
Effects of probucol on restenosis after percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Anticholesteremic Agents; Cardiovascular Agents; Combined Modality Therapy; Coronary Disease; Humans | 2015 |
[Treatment of high blood cholesterol in patients with coronary heart disease].
Topics: Anion Exchange Resins; Bezafibrate; Clinical Trials as Topic; Coronary Disease; Humans; Hydroxymethy | 1994 |
[Prevention of postangioplasty restenosis].
Topics: Angioplasty, Balloon, Coronary; Atherectomy, Coronary; Clinical Trials as Topic; Coated Materials, B | 2003 |
[Treatment of high blood cholesterol in patients with coronary heart disease].
Topics: Anion Exchange Resins; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Di | 2003 |
[Research and developmental strategy of anti-dyslipidemic agents].
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Apolipoprotein A-I; Carrier Proteins; Chole | 2007 |
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl | 1984 |
Hyperlipidemia: perspectives in diagnosis and treatment.
Topics: Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Coronary Disease; Diet, Fat-Re | 1995 |
Dyslipidemia and coronary artery disease.
Topics: Arteriosclerosis; Cholesterol; Coronary Disease; Drug Therapy, Combination; Exercise; Gemfibrozil; H | 1994 |
Medical management of hyperlipidemic states.
Topics: Coronary Disease; Diet Therapy; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Pancrea | 1994 |
[Anti-atherogenic drugs].
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Bezafibrate; Coronary Disea | 1998 |
[Discrimination between the effects of hypolipidemic and antiatherogenic drugs: probucol pharmacokinetics (review of the literature)].
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Animals; Anticholesteremic Agents; Arterioscle | 2000 |
Probucol.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Apolipoproteins E; Arteriosclerosis; Cardiovascular | 2000 |
[Nicotinic acid and the derivative].
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Hum | 2001 |
[Antioxidants].
Topics: Animals; Antioxidants; Arteriosclerosis; Ascorbic Acid; Carotenoids; Clinical Trials as Topic; Coron | 2001 |
Cholesterol-lowering drugs as cardioprotective agents.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA | 1992 |
Drug therapy in dyslipidemia.
Topics: Anticholesteremic Agents; Bile Acids and Salts; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA | 1990 |
Drug treatment of dyslipoproteinemia.
Topics: Bile Acids and Salts; Clofibrate; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Humans; | 1990 |
Lipid lowering effects on cardiovascular morbidity and mortality. Clinical evidence and therapeutic guidelines.
Topics: Cholesterol; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Coronary Disease; Follow-Up | 1988 |
Reducing cardiac deaths with hypolipidemic drugs.
Topics: Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Feeding Behavior; Gemfi | 1987 |
The diagnosis and management of hyperlipidemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibr | 1986 |
20 trials available for probucol and Coronary Disease
| Article | Year |
|---|---|
The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study.
Topics: Aged; Antioxidants; Combined Modality Therapy; Contrast Media; Coronary Disease; Creatinine; Cystati | 2018 |
Effects of probucol on contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention.
Topics: Acute Kidney Injury; Aged; Antioxidants; China; Contrast Media; Coronary Angiography; Coronary Disea | 2019 |
Relationship between free-radical lipid oxidation and efficiency of coronary angioplasty in coronary patients.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Antioxidants; Combined Modality Therapy; Coronary Angio | 2007 |
Effects of AGI-1067 and probucol after percutaneous coronary interventions.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Coronary D | 2003 |
Novel cardiac therapies and innocent by standers.
Topics: Antioxidants; Coronary Disease; Double-Blind Method; Humans; Probucol | 2008 |
[A long-term (9 years) clinical study of the safety and efficacy of probucol, and an analysis of morbidity and mortality rates (author's transl)].
Topics: Adult; Cholesterol; Clinical Trials as Topic; Coronary Disease; Female; Follow-Up Studies; Humans; H | 1980 |
[Comparative effects of probucol and placebo on blood cholesterol in patients on long-term treatment (author's transl)].
Topics: Cholesterol; Coronary Disease; Double-Blind Method; Humans; Hyperlipoproteinemia Type II; Hyperlipop | 1980 |
[Ticlopidine may prevent subtotal or total occlusion of dilated lesions after percutaneous coronary angioplasty].
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; F | 1993 |
Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Constriction, Pathologic; Cor | 1996 |
Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cell Division; Cholesterol; C | 1996 |
Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group.
Topics: Angioplasty, Balloon, Coronary; Antioxidants; Ascorbic Acid; beta Carotene; Coronary Angiography; Co | 1997 |
Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Antioxidants; Cholesterol; Combined | 1997 |
Prevention of restenosis after angioplasty in small coronary arteries with probucol.
Topics: Aged; Angioplasty, Balloon; Anticholesteremic Agents; Antioxidants; Coronary Angiography; Coronary D | 1998 |
Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cilostazol; Coronary Angiography; C | 1998 |
Effect of probucol on repeat revascularization rate after percutaneous transluminal coronary angioplasty (from the Probucol Angioplasty Restenosis Trial [PART]).
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Disease; Disease-Free Survival; F | 2000 |
Impact of residual plaque burden after balloon angioplasty in the MultiVitamins and Probucol (MVP) trial.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Antioxidants; Coronary Disease; Coronary V | 2001 |
Cholesterol-lowering drugs as cardioprotective agents.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA | 1992 |
Long-term use of probucol in the multifactorial primary prevention of vascular disease.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Cerebrovascular Disorders; Cholesterol, HDL; C | 1986 |
Lipid lowering effects on cardiovascular morbidity and mortality. Clinical evidence and therapeutic guidelines.
Topics: Cholesterol; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Coronary Disease; Follow-Up | 1988 |
Effects of combined probucol-colestipol treatment for familial hypercholesterolemia and coronary artery disease.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Colestipol; | 1986 |
37 other studies available for probucol and Coronary Disease
| Article | Year |
|---|---|
Combined effect of atorvastatin and probucol on plasma cystatin C levels and severity of coronary lesion in patients with borderline coronary lesion.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Cystatin C; Female; Heptanoic Acids; | 2012 |
Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse.
Topics: Age Factors; Animals; Anticholesteremic Agents; Apolipoproteins E; CD36 Antigens; Cell Differentiati | 2003 |
Effect of antioxidant probucol on cell-mediated LDL oxidation in vitro and in vivo.
Topics: Anticholesteremic Agents; Antioxidants; Cells, Cultured; Coronary Disease; Endothelial Cells; Humans | 2003 |
CETP levels rather than polymorphisms as markers of coronary risk: healthy athlete with high HDL-C and coronary disease--effectiveness of probucol.
Topics: Adult; Anticholesteremic Agents; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, | 2006 |
American Heart Association - Scientific Sessions 2006. Cell therapies for ischemic tissues and treatments for lipid metabolism disorders.
Topics: Animals; Cell- and Tissue-Based Therapy; Cholesterol, LDL; Coronary Disease; Endothelial Cells; Eryt | 2007 |
Lowered HDL cholesterol and incidence of ischaemic heart disease.
Topics: Cholesterol; Cholesterol, HDL; Coronary Disease; Humans; Hypercholesterolemia; Lipoproteins, HDL; Ph | 1981 |
Probucol and ischaemic heart disease.
Topics: Cholesterol; Cholesterol, HDL; Coronary Disease; Humans; Lipoproteins, HDL; Phenols; Probucol | 1981 |
Platelet function in familial hypercholesterolaemia in South Africa and the effects of probucol.
Topics: Adolescent; Adult; Aged; beta-Thromboglobulin; Child; Cholesterol; Coronary Disease; Female; Humans; | 1982 |
[Evaluation of the effectiveness of hypolipidemic preparations in coronary arteriosclerosis].
Topics: Coronary Disease; Drug Evaluation; Glucose Tolerance Test; Humans; Hyperlipoproteinemias; Hypolipide | 1984 |
Hyperlipidemia: reducing the chances of cardiovascular disease.
Topics: Cholesterol; Cholestyramine Resin; Clofibrate; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemia | 1984 |
[Effect of probucol on lipid metabolism and the clinical course of ischemic heart disease and arteriosclerosis obliterans of the vessels of the lower extremities].
Topics: Adult; Aged; Angina Pectoris; Arteriosclerosis Obliterans; Chronic Disease; Coronary Disease; Drug E | 1984 |
Effect of probucol on the activity of postheparin plasma lipoprotein lipase and hepatic lipase.
Topics: Apolipoprotein A-I; Apolipoproteins; Cholesterol; Cholesterol, HDL; Coronary Disease; Heparin; Human | 1981 |
Clinical experience with probucol with special emphasis on mode of action and long-term treatment.
Topics: Cholesterol; Coronary Disease; Electrocardiography; Heart Diseases; Humans; Hypercholesterolemia; Ph | 1982 |
Correlative design of electrophoretic and ultracentrifugal investigation of metabolic effects of probucol.
Topics: Blood Protein Electrophoresis; Coronary Disease; Diet; Electrophoresis, Agar Gel; Humans; Hyperchole | 1982 |
Ultracentrifugal study of metabolic effects of probucol: plasma lipoproteins in patients with proven coronary artery disease.
Topics: Adsorption; Cholesterol; Coronary Disease; Humans; Lipoproteins; Molecular Weight; Phenols; Probucol | 1982 |
Is it harmful to lower HDL levels?
Topics: Cholesterol; Cholesterol, HDL; Coronary Disease; Depression, Chemical; Diet; Humans; Lipoproteins, H | 1981 |
Effect of probucol on plasma lipids and lipoproteins in type IIb hyperlipoproteinemia.
Topics: Adult; Cholesterol; Coronary Disease; Humans; Hyperlipoproteinemia Type II; Hypolipoproteinemias; Li | 1980 |
Probucol decreases neointimal formation in a swine model of coronary artery balloon injury. A possible role for antioxidants in restenosis.
Topics: Animals; Antioxidants; Catheterization; Coronary Disease; Coronary Vessels; Female; Probucol; Recurr | 1993 |
Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association.
Topics: Cholesterol, Dietary; Coronary Disease; Diet; Fatty Acids, Omega-3; Female; Humans; Hyperlipidemias; | 1993 |
Restenosis revisited--new targets, new therapies.
Topics: Angioplasty, Balloon, Coronary; Antioxidants; Coronary Disease; Drug Therapy, Combination; Humans; P | 1997 |
Long-term probucol treatment reverses the severity of myocardial injury in watanabe heritable hyperlipidemic rabbits.
Topics: Administration, Oral; Animals; Antioxidants; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Cor | 1997 |
Probucol and multivitamins in the prevention of restenosis after coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Antioxidants; Cholesterol, HDL; Coronary D | 1997 |
Probucol and multivitamins in the prevention of restenosis after coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Antioxidants; Confounding Factors, Epidemiologic; Coronary Disease; | 1997 |
Probucol and multivitamins in the prevention of restenosis after coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Antioxidants; Coronary Disease; Electrocardiography; Female; Humans; | 1997 |
Vessel size, antioxidants, and restenosis: never too small, not too little, but often too late.
Topics: Angioplasty, Balloon; Anticholesteremic Agents; Antioxidants; Clinical Trials as Topic; Coronary Dis | 1998 |
Patient care after percutaneous coronary artery interventions.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Disease; Humans; Probucol; Recurr | 1998 |
Can an old drug prevent restenosis after PTCA?
Topics: Angioplasty, Balloon, Coronary; Antioxidants; Coronary Disease; Humans; Probucol; Secondary Preventi | 1998 |
Secondary prevention with lipid lowering therapy in familial hypercholesterolemia: a correlation between new evolution of stenotic lesion and achieved cholesterol levels after revascularization procedures.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholestyramine Resin; Coronary Arter | 1999 |
[Reduction in the rates of restenosis after coronary angioplasty with simvastatin and probucol].
Topics: Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol; Coronary Disease; Femal | 1999 |
[New strategies in the treatment of restenosis].
Topics: Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Anticholesteremic Agents; Athe | 2000 |
[Treatment of hyperlipidemia].
Topics: Blood Component Removal; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Coronary Disease; Dieta | 1992 |
Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer.
Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Corneal | 1988 |
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel.
Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Coronary Disease; Diet | 1988 |
The pharmacology and therapeutics of lipid-lowering drugs.
Topics: Adult; Bile Acids and Salts; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitor | 1987 |
[Treatment of ischemic heart disease with probucol].
Topics: Adult; Coronary Disease; Humans; Middle Aged; Phenols; Probucol | 1986 |
A symposium: new developments in the treatment of hypercholesterolemia--probucol. Introduction.
Topics: Cholesterol, LDL; Coronary Disease; Humans; Hypercholesterolemia; Lipoproteins, LDL; Phenols; Probuc | 1986 |
Nonprogression of coronary artery atherosclerosis in homozygous familial hypercholesterolemia after 31 months of repetitive plasma exchange.
Topics: Achilles Tendon; Adult; Angiography; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Coronary D | 1986 |